title: Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.
abstract: BACKGROUND
  The most commonly used chemotherapeutic regimens in the treatment of metastatic breast cancer (MBC) include anthracyclines and taxanes. In our study, we investigated the efficacy and tolerability of cisplatin plus gemcitabine combination chemotherapy regimen in patients with MBC, who exhibited disease progression after anthracycline- and taxane-based chemotherapy.
  
  
  METHODS
  Thirty-three patients with taxane/anthracycline-resistant MBC have been treated with gemcitabine 1,000 mg/m(2) intravenously and cisplatin 30 mg/m(2) intravenously on days 1 and 8 of a 3-week treatment cycle.
  
  
  RESULTS
  Thirty-one patients were assessable for response. One of the 31 patients (3.2%) showed complete response, while 7 patients (22.6%) showed partial response; the objective response rate was 25.8%. Stable and progressive disease was observed in 6 (19.4%) and 17 patients (54.8%), respectively. The median time to progression was 4 months (95% CI 2.15-5.85). The median survival time of all patients was 9.5 months (95% CI 7.86-11.14).
  
  
  CONCLUSIONS
  Gemcitabine and cisplatin combination therapy is moderately active and safe in patients with MBC previously treated with anthracycline and taxanes.
authors.affiliation: Department of Medical Oncology, Ataturk Research and Training Hospital, Izmir, Turkey. isilsomali@gmail.com
authors.forename: Isil
authors.initials: I
authors.lastname: Somali
authors.forename: Ahmet
authors.initials: A
authors.lastname: Alacacioglu
authors.forename: Mustafa Oktay
authors.initials: MO
authors.lastname: Tarhan
authors.forename: Nezih
authors.initials: N
authors.lastname: Meydan
authors.forename: Cigdem
authors.initials: C
authors.lastname: Erten
authors.forename: Songul
authors.initials: S
authors.lastname: Usalp
authors.forename: Ugur
authors.initials: U
authors.lastname: Yilmaz
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage* / Q000633:toxicity; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000633:toxicity; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use; D000093542:Gemcitabine
chemical_list: D018943:Anthracyclines; D001952:Bridged-Ring Compounds; D043823:Taxoids; D003841:Deoxycytidine; C080625:taxane; D002945:Cisplatin; D000093542:Gemcitabine